title: Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F).
abstract: Contribution of host-related cytokine release in the course of pretransplant conditioning to early tissue damage and induction of acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) has been shown in experimental models. We performed a clinical phase I/II trial applying a monoclonal antibody neutralizing human tumor necrosis alpha (TNF alpha) during pretransplant conditioning as additional prophylaxis in high-risk patients admitted to allogeneic BMT; TNF alpha serum levels and clinical courses in 21 patients receiving anti-TNF alpha prophylaxis were compared with data from 22 historical controls. Absence of significant release of TNF alpha in the period of busulphan (BUS) treatment, but significant induction of TNF alpha by total body irradiation (TBI) and cyclophosphamide (CY) conditioning were correlated with significantly earlier onset of acute GVHD in patients receiving TBI/CY regimens as compared with BUS/CY-treated patients. Prophylactic application of monoclonal anti-TNF alpha seemed to postpone onset of acute GVHD from day 15 to day 25 (P < .05) after TBI/CY and from day 33 to day 53 after BUS/CY (P < .10) conditioning. Application of monoclonal anti-TNF alpha in low and intermediate doses was safe and not associated with an increased incidence of infectious or hematologic complications. Thus, our data provide indirect and direct evidence for involvement of conditioning-related cytokine release in induction of early acute GVHD in the clinical setting and support further investigation of this novel approach in randomized trials.
authors.affiliation: Medizinische Klinik III, Klinikum Grosshadern, München, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Holler
authors.forename: H J
authors.initials: HJ
authors.lastname: Kolb
authors.forename: J
authors.initials: J
authors.lastname: Mittermüller
authors.forename: M
authors.initials: M
authors.lastname: Kaul
authors.forename: G
authors.initials: G
authors.lastname: Ledderose
authors.forename: T
authors.initials: T
authors.lastname: Duell
authors.forename: B
authors.initials: B
authors.lastname: Seeber
authors.forename: M
authors.initials: M
authors.lastname: Schleuning
authors.forename: R
authors.initials: R
authors.lastname: Hintermeier-Knabe
authors.forename: B
authors.initials: B
authors.lastname: Ertl
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000936:Antigen-Antibody Complex / Q000378:metabolism; D016026:Bone Marrow Transplantation / Q000379:methods*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D014409:Tumor Necrosis Factor-alpha